FDA Approves SimpleScreen: A Second Blood Test Aims to Close Colorectal Cancer Screening Gap

FDA's SimpleScreen Approval and the 60 Million Unscreened

The US Food and Drug Administration has approved Freenome's SimpleScreen CRC blood test as a colorectal cancer screening option for average-risk adults, making it the second blood-based test of its kind to reach the US market after the Shield test was cleared in 2024.

SimpleScreen works by detecting patterns of CpG methylation, DNA changes that often appear early in cancer development, in a standard blood draw. Results generally arrive within about two weeks, and any positive result must be followed by a colonoscopy to complete the screening process, according to the company and Paul Limburg, chief screening medical officer at Abbott Cancer Diagnostics. In the PREEMPT CRC clinical study of more than 48,000 participants, the test detected roughly 8 in 10 colorectal cancers and returned negative results for about 9 in 10 people without colorectal cancer or advanced precancerous lesions.

The approval arrives against a stark public health backdrop. Colorectal cancer is the second leading cause of cancer-related deaths worldwide, and early-onset colorectal cancer is the leading cause of cancer-related death among men and women under age 50. Guidelines recommend screening for average-risk adults starting at age 45, yet an estimated 60 million eligible Americans are not up to date. Preparation, discomfort, embarrassment, cost and fear have kept many people away from colonoscopy and stool-based tests. Supporters hope a simple blood draw will bring some of those people into screening earlier, when treatment is most effective.

Why a Second Blood Test Matters for Cancer Detection

Where SimpleScreen Fits in the Screening Hierarchy

The approval expands patient choice, but it does not put blood tests on equal footing with existing methods. In the article, Limburg notes that the American Cancer Society still identifies stool-based tests such as Cologuard Plus and visual exams such as colonoscopy as preferred options, with blood-based screening recommended for people who decline or do not complete those tests. The American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy reach a similar conclusion: blood tests are better than no screening, but less effective than established options.

The trial numbers show why. A test that finds about 8 in 10 colorectal cancers leaves one in five undetected, and a negative result for about 9 in 10 people without the disease means roughly one in ten screened patients could receive a false alarm requiring a follow-up colonoscopy. For population screening, that is a meaningful trade-off: higher participation against lower per-test accuracy and an added burden on endoscopy capacity.

The Competitive Stakes for Freenome, Shield and Cologuard

Freenome enters a market that already has the Shield blood test, approved in 2024, and an entrenched stool test in Cologuard Plus. The practical battleground will be coverage and reimbursement rather than approval alone. Freenome can point to a large PREEMPT CRC dataset of more than 48,000 participants in discussions with insurers and health systems, but it must also overcome the guideline hierarchy that favors colonoscopy and stool testing. Limburg's comments should be read with that commercial context in mind: he is a senior medical officer at Abbott, a company with its own cancer diagnostics business, so his endorsement of the new test aligns with an interest in expanding the overall screening market.

Whether a Blood Test Will Close the 60 Million Gap

The convenience factor is real: no bowel preparation, no scope, no at-home stool handling. Research cited in the article suggests adherence to blood-based screening could reach 95%, and most participants were willing to complete a blood test if it was free or covered by insurance. But convenience alone will not close the gap. The 60 million unscreened adults include people with limited healthcare access, cost concerns and no strong provider recommendation, and no single modality reaches all of them. The meaningful test of SimpleScreen will be whether insurers cover it, whether primary care doctors actively offer it, and whether people with positive results actually complete the follow-up colonoscopy.

What Eligible Adults and Providers Should Consider Before Choosing a Blood Test

For adults 45 and older who have put off screening, the new approval adds a genuinely less intimidating entry point, but it comes with trade-offs that matter before choosing a test.

• Adults who have delayed screening because of colonoscopy preparation or stool-test discomfort can ask a clinician about the SimpleScreen or Shield blood tests, which require only a blood draw and return results in about two weeks.
• Expect the blood test to be positioned as a backstop rather than a first choice: professional guidelines discussed in the article still list colonoscopy and stool-based tests as preferred, reserving blood tests for people who decline those options.
• If a blood test is positive, plan for a follow-up colonoscopy to complete screening; a positive blood result alone does not diagnose cancer.
• Providers should pair the offer with an explicit recommendation and a system for tracking follow-through, since study data in the article shows the test misses about 2 in 10 colorectal cancers even while real-world adherence to blood-based screening may reach 95%.